Related Resources
  • Industry Reports
  • 2026

Washington State Life Science Investment Report – July 2026
  • Policy Blog
  • 2026

Policy Blog – August 31, 2026 – NSCEB Visits Seattle to Discuss U.S. Biotechnology Competitiveness

Last week, Life Science Washington, in partnership with Arzeda, hosted a Seattle field visit by the National Security Commission on Emerging Biotechnology (NSCEB) as part of its Biotech Across America Roadshow.  Established by Congress, NSCEB has spent the past several years examining what the United States must do to maintain its leadership in biotechnology, with particular attention to growing competition […]
  • Policy Blog
  • 2026

Policy Blog – August 13, 2026 – Industry Welcomes New PDUFA VIII Agreement

The FDA and biopharmaceutical industry have reached an important agreement on the next iteration of the Prescription Drug User Fee Act (PDUFA), setting the stage for congressional reauthorization of a program that has been central to the FDA’s drug review process for more than three decades.  The FDA recently released its proposed PDUFA VIII commitment letter, outlining […]
  • Industry Reports
  • 2026

Washington State Life Science Investment Report – June 2026